Extremities The commercialization of Bioretec’s RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement byJosh SandbergNovember 20, 2024
Spine Inside information: Bioretec updates its product development strategy by accelerating the product development of RemeOs™ Spinal Interbody Cage byJosh SandbergOctober 4, 2024
Financial Bioretec Ltd’s half-year report January-June 2024: RemeOs™ trauma screw controlled launch in the U.S. yielded expected positive clinical results byJosh SandbergAugust 15, 2024
Extremities Bioretec reports successful clinical outcomes from U.S. controlled launch of RemeOs™ trauma screw: fracture healing confirmed in 100% of surgical procedures byTim AllenJune 19, 2024
Top Stories Bioretec Appoints Frank Sarcone as Vice President of Sales for the US and a member of the Management Team byJosh SandbergJune 18, 2024
Financial Bioretec Ltd’s business review January-March 2024: Controlled launch in the U.S. progresses byTim AllenMay 16, 2024
Financial Bioretec Ltd’s Annual Report and Financial Statements 2023 published byJosh SandbergMarch 15, 2024
Regulatory Spine Top Stories Inside information: Bioretec has been granted FDA Breakthrough Device Designation status for its RemeOs™ Spinal Interbody Cage byJosh SandbergMarch 14, 2024
Financial Bioretec Ltd’s financial statements bulletin 2023: Another successful year in the growth trajectory byJosh SandbergFebruary 16, 2024
